File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Reduction of hepatitis B core related antigen by long term nucleoside nucleotide analogue therapy and its correlation with intrahepatic HBV DNA reduction

TitleReduction of hepatitis B core related antigen by long term nucleoside nucleotide analogue therapy and its correlation with intrahepatic HBV DNA reduction
Authors
KeywordsMedical sciences
Endocrinology
Issue Date2015
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 24th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL 2015), Istanbul, Turkey, 12-15 March 2015. In Hepatology International, 2015, v. 9 suppl. 1, p. S202, abstract no. 1282 How to Cite?
AbstractOBJECTIVE: We aimed to investigate the reduction of hepatitis B corerelated antigen (HBcrAg) in patients with long term nucleoside/ nucleotide analogue (NA) therapy. METHODS: Forty-three patients (median age: 43 years, range: 24–63 years) who had been on continuous (median follow-up duration: 10 years; range 5–12 years) NA therapy, including lamivudine, adefovir, telbivudine, entecavir, and tenofovir, were recruited. All patients had liver biopsies at baseline and at the last follow-up. HBcrAg (detection limit: 3 log U/mL) were measured using a Lumipulse HBcrAg assay (Fujirebio, Japan). Intrahepatic total HBV DNA (ihHBV-DNA) and covalently closed circular DNA (cccDNA) were assayed by real-time PCR. RESULTS: At baseline, the median levels of HBcrAg, ihHBV-DNA, and cccDNA were 6.7 log U/mL, 286 copies/cell, and 7.3 copies/cell, respectively. Baseline level of HBcrAg correlated positively with that of ihHBV-DNA (r = 0.568, P\0.0001), and cccDNA (r = 0.559, P\0.0001). At the time of last biopsy, 12 (28 %) patients had undetectable HBcrAg (median: 3.8; range:\3–5.7 log U/mL). All patients had detectable ihHBV-DNA (median: 0.35 copies/cell), and 21 (49 %) patients had undetectable cccDNA. The median logarithmic reductions of HBcrAg, ihHBV-DNA, and cccDNA were 2.7 log U/mL, 2.81 log copies/cell, and 2.94 log copies/cell, respectively. There was a positive correlation between the logarithmic reduction of HBcrAg and ihHBV-DNA (r = 0.550, P\0.001) and cccDNA (r = 0.419, P = 0.005). CONCLUSION: The marked reduction of HBcrAg, together with the reduction in ihHBV-DNA and cccDNA, further supports the effectiveness of long-term nucleoside/tide analogue therapy in potentially eradicating HBV from chronic carriers
DescriptionConference Theme: New Horizons from East to west in Hepatology
Topic 11 - Hepatitis B: no. 1282
This journal suppl. entitled: Conference Abstracts: 24th Annual Conference of APASL, March 12-15, 2015, Istanbul, Turkey
Persistent Identifierhttp://hdl.handle.net/10722/214128
ISSN
2015 Impact Factor: 1.125
2015 SCImago Journal Rankings: 0.669

 

DC FieldValueLanguage
dc.contributor.authorWong, D-
dc.contributor.authorKopaniszen, M-
dc.contributor.authorSeto, WK-
dc.contributor.authorFung, J-
dc.contributor.authorHung, I-
dc.contributor.authorYoung, JLP-
dc.contributor.authorYuen, JCH-
dc.contributor.authorNgai, VWS-
dc.contributor.authorYuen, MF-
dc.contributor.authorLai, CL-
dc.date.accessioned2015-08-21T03:21:41Z-
dc.date.available2015-08-21T03:21:41Z-
dc.date.issued2015-
dc.identifier.citationThe 24th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL 2015), Istanbul, Turkey, 12-15 March 2015. In Hepatology International, 2015, v. 9 suppl. 1, p. S202, abstract no. 1282-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/214128-
dc.descriptionConference Theme: New Horizons from East to west in Hepatology-
dc.descriptionTopic 11 - Hepatitis B: no. 1282-
dc.descriptionThis journal suppl. entitled: Conference Abstracts: 24th Annual Conference of APASL, March 12-15, 2015, Istanbul, Turkey-
dc.description.abstractOBJECTIVE: We aimed to investigate the reduction of hepatitis B corerelated antigen (HBcrAg) in patients with long term nucleoside/ nucleotide analogue (NA) therapy. METHODS: Forty-three patients (median age: 43 years, range: 24–63 years) who had been on continuous (median follow-up duration: 10 years; range 5–12 years) NA therapy, including lamivudine, adefovir, telbivudine, entecavir, and tenofovir, were recruited. All patients had liver biopsies at baseline and at the last follow-up. HBcrAg (detection limit: 3 log U/mL) were measured using a Lumipulse HBcrAg assay (Fujirebio, Japan). Intrahepatic total HBV DNA (ihHBV-DNA) and covalently closed circular DNA (cccDNA) were assayed by real-time PCR. RESULTS: At baseline, the median levels of HBcrAg, ihHBV-DNA, and cccDNA were 6.7 log U/mL, 286 copies/cell, and 7.3 copies/cell, respectively. Baseline level of HBcrAg correlated positively with that of ihHBV-DNA (r = 0.568, P\0.0001), and cccDNA (r = 0.559, P\0.0001). At the time of last biopsy, 12 (28 %) patients had undetectable HBcrAg (median: 3.8; range:\3–5.7 log U/mL). All patients had detectable ihHBV-DNA (median: 0.35 copies/cell), and 21 (49 %) patients had undetectable cccDNA. The median logarithmic reductions of HBcrAg, ihHBV-DNA, and cccDNA were 2.7 log U/mL, 2.81 log copies/cell, and 2.94 log copies/cell, respectively. There was a positive correlation between the logarithmic reduction of HBcrAg and ihHBV-DNA (r = 0.550, P\0.001) and cccDNA (r = 0.419, P = 0.005). CONCLUSION: The marked reduction of HBcrAg, together with the reduction in ihHBV-DNA and cccDNA, further supports the effectiveness of long-term nucleoside/tide analogue therapy in potentially eradicating HBV from chronic carriers-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology International-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/10.1007/s12072-015-9609-1-
dc.subjectMedical sciences-
dc.subjectEndocrinology-
dc.titleReduction of hepatitis B core related antigen by long term nucleoside nucleotide analogue therapy and its correlation with intrahepatic HBV DNA reduction-
dc.typeConference_Paper-
dc.identifier.emailWong, D: danywong@hku.hk-
dc.identifier.emailKopaniszen, M: malkop@hku.hk-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailFung, J: jfung@hkucc.hku.hk-
dc.identifier.emailHung, I: ivanhung@hkucc.hku.hk-
dc.identifier.emailYoung, JLP: jlpyoung@hkucc.hku.hk-
dc.identifier.emailYuen, JCH: jchyuen@hkucc.hku.hk-
dc.identifier.emailNgai, VWS: vinngai@hkucc.hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.authorityWong, D=rp00492-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityFung, J=rp00518-
dc.identifier.authorityHung, I=rp00508-
dc.identifier.authorityYuen, MF=rp00479-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.doi10.1007/s12072-015-9609-1-
dc.identifier.hkuros248059-
dc.identifier.volume9-
dc.identifier.issuesuppl. 1-
dc.identifier.spageS202, abstract no. 1282-
dc.identifier.epageS202, abstract no. 1282-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats